Allergy Therapeutics Share Discussion Threads

[jpuff] 29/3/2023 07:45

What the hell is going on here?

[jpuff] 29/3/2023 07:42

Allergy Therapeutics PLC Publication of Interim Results DelayedSource: UK Regulatory (RNS & others)TIDMAGYRNS Number : 5433UAllergy Therapeutics PLC29 March 2023Allergy Therapeutics plc("Allergy Therapeutics", "ATL", the "Company" or the "Group")Publication of Interim Results Delayed29 March 2023 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it will not publish its interim results for the six-month period to 31 December 2022 by 31 March 2023.On 29 December 2022, the Company announced a delay in the publication of its annual report and accounts for the year to 31 June 2022 due to delays in completing the audit. Consequently, the Company's shares were suspended from trading on 3 January 2023 and remain suspended.The Company is actively working to finalise the audit and publication of its 2022 annual report and accounts and its interim results. Allergy Therapeutics remains in active discussions regarding its funding situation and will update the market in due course. For further information on the Company , please visit the website : www.allergytherapeutics.com . This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.- ENDS -For further information, please contact:Allergy Therapeutics+44 (0) 1903 845 820Manuel Llobet, Chief Executive OfficerMartin Hopcroft, Interim Chief Financial OfficerPanmure Gordon (Nominated Adviser and Broker)[phone]Freddy Crossley, Emma Earl, Corporate FinanceRupert Dearden, Corporate BrokingConsilium Strategic Communications+44 20 3709 5700Mary-Jane Elliott / David Daley / Davide [e-mail] for editors:About Allergy TherapeuticsAllergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite, and peanut.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNORPPUPUWUPWPGR(END) Dow Jones NewswiresMarch 29, 2023 02:00 ET (06:00 GMT)

[jimmyloser] 27/3/2023 09:43

The two large shareholders still invested many millions in here so I figure confidence on success is very high
impo

[raleigh43] 27/3/2023 09:29

They have mostly institutions as investors and very few PIs. So no rush in their eyes.
I sold before suspension as better to take a hit than wait for months.
But, I follow this as I still see the peanut allergy as a big winner if they can get it to market, but still a long way to go before that happens.

[jimmyloser] 27/3/2023 06:27

We need to be seeing more of you wizzkid 211 with news that the accounts have been signed off and we are returning to market.

[wizzkid211] 27/3/2023 06:04

Allergy Therapeutics PLC Patients dosed in VLP Peanut PROTECT trial
27/03/2023 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Monday 27 March 2023

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 2185U

Allergy Therapeutics PLC

27 March 2023

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics announces dosing of patients has commenced in Phase I PROTECT trial investigating novel peanut allergy vaccine candidate, VLP Peanut

27 March 2023 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first application of VLP Peanut in peanut allergic patients has commenced with the Group's innovative, short-course peanut allergy vaccine candidate in the Phase I PROTECT trial. The first-in-human study is evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy.

Allergy Therapeutics' wholly-owned, subcutaneous, recombinant vaccine candidate incorporates novel virus-like particle (VLP) technology, which enhances the body's immune response by making the peanut allergen resemble an inactive virus.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

- ENDS -

[amishp67] 22/3/2023 14:29

Let's hope this doesn't drag into April

[stablehound] 21/3/2023 14:44

How a Company can get itself into a mess such as this is very hard to understand. I communicated with them before the AGM and received an anodyne response which is not surprising but when I recently sent a polite chaser to see whether anyone was still alive I got no reply at all. In my experience if a share is suspended there is a fair amount of pressure on Directors to resolve the outstanding issues not only from the Stock Exchange but also from the NOMAD whose reputation is done no good by being associated with such incompetance. There were, apparently, no sign of any hair shirts at the AGM; sometimes a little humility can be positive but then not many listed companies are so tightly held, even if the largest shareholder apparently no longer wants to be associated with you.

The feeling I have is that the Company has never dealt with its minority shareholders in a mature manner and has spun stories which never told the true position the Company found itself in. It would be interesting to fact check their statements. At very least there should be sone departures at very senior level. Hopefully the major shareholders are suitably engaged.

[jimmyloser] 20/3/2023 17:04

I personally don't think so, AGY are doing everything by the book in my eyes though I do find the delay returning to market rather frustrating.

I trust Manuel.

I actually think they should let the markets calm a little.

impo/dyor

[jpuff] 20/3/2023 11:23

Hmm have we been well and truly mugged?

[timbo003] 17/3/2023 12:33

>>>davesailing

They can remain suspended for 6 months, thereafter they either relist or their Aim listing is cancelled

[davesailing] 17/3/2023 11:23

After 10 weeks, there is still no news on when suspension will be lifted..... Is there a time limit on how long the suspension can last or when shareholders must be provided with an update?

[jimmyloser] 13/3/2023 08:45

There may well be more to this than meets the eye. Are they waiting for to be able to report on the two trials and if you recall they did mention a USA listing some time ago.

For a P.I. in AGY, I have a sizeable stake and feel that news should be updated with us all.

dyor/impo

[genises] 13/3/2023 08:12

Looks as if the chairman doesn’t care about us poor small investors.Obviously keeps the larger shareholder involved.
When are we been taken over.

[raleigh43] 10/3/2023 13:40

Glad i sold as suspended shares feel like purgatory.

Sort it out AGY!

[jimmyloser] 06/3/2023 15:27

????????????????????????????????

Over two months now!

[jimmyloser] 03/3/2023 07:09

BREAKING NEWS...NON RNS

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

PDMR Dealing

Issue of 33,333,332 Warrants

3 March 2023 - Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that, further to the Company's announcement on 29 September 2022 regarding the subscription and debt financing, on 28 February 2023 it issued 33,333,332 warrants to subscribe for new Ordinary Shares ("Warrants").

As previously announced, in conjunction with the issue of Loan Notes, the Company agreed to issue 33,333,332 Warrants to Southern Fox and ZQ Capital, to subscribe for new Ordinary Shares at a Warrant Exercise price of 30 pence per Warrant. The Warrants are exercisable for a period of five years from the Purchase Date of the Loan Notes.

Following the issue of Warrants Southern Fox and ZQ Capital will hold the following Warrants over Ordinary Shares in the Company:

-- Southern Fox: 16,666,666 Warrants; and
-- ZQ Capital: 16,666,666 Warrants.
Capitalised terms used and not defined in this announcement have the meanings given to them in the announcement from 29 September 2022.

For further informatio

[genises] 01/3/2023 18:50

Agree jimmyloser
The chairman should step down or take a £200,000 reduction in his huge salary

[jimmyloser] 28/2/2023 18:23

It is and has been nothing less than a debacle and in my eyes a huge stain on the character of a potentially world class business.
Impo

[jpuff] 28/2/2023 18:12

It's been more of a slide than a bumpy ride from 40p to 6p

[jimmyloser] 28/2/2023 17:19

All will be revealed and soon.........impo
I remain relaxed but expect a bumpy ride for a month or two.

[1kckeith] 28/2/2023 13:47

I don't think the £10m will be forthcoming. I hope I'm wrong but fear that the £10m is part of the problem, the other parts being the 18% reduction in sales and the consequent loss of the NatWest facility. I can't imagine that something so big as the cretinous self-inflicted shut-down and all that followed from it did not trigger a right on the part of the £10m lenders to refrain from making the loan.

[amishp67] 27/2/2023 14:59

We usually get half yearly results on the 3rd of March every year. Lets hope we still get this and get a trading update on the suspension with it.I'm also hoping there isn't additional funding needed on top of then 10 million loan notes (they refer to near term lending) so hopefully the loan notes is the near term lending

[farmergeorge] 27/2/2023 14:54

It's all been a bit of a drawnout shambles. Lets's hope this will now be resolved and the shares start trading.

[jimmyloser] 27/2/2023 14:38

The recent trading update indicates that they ....expect... £10million into their bank tomorrow


The cash balance at 31 December 2022 was GBP15.2m (30 June 2022: GBP20.5m). Pursuant to the subscription and debt financing announced on 29 September 2022, the Company has received GBP7m from the issue of new ordinary shares and

expects

to receive GBP10m from the issue of loan notes on 28 February 2023.

If I was expecting £10million on the 28th, it would be a very important day indeed. :-)

impo/dyor